These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19455464)

  • 1. Bright CD38 expression is an indicator of MYC rearrangement.
    Maleki A; Seegmiller AC; Uddin N; Karandikar NJ; Chen W
    Leuk Lymphoma; 2009 Jun; 50(6):1054-7. PubMed ID: 19455464
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry.
    Mandelker DL; Dorfman DM; Li B; Pozdnyakova O
    Leuk Lymphoma; 2014 Nov; 55(11):2592-6. PubMed ID: 24397618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
    Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
    Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis.
    Lynnhtun K; Renthawa J; Varikatt W
    Pathology; 2014 Apr; 46(3):211-5. PubMed ID: 24614699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicolour flow cytometric assay for c-MYC protein in B-cell lymphoma.
    Alayed K; Schweitzer K; Awadallah A; Shetty S; Turakhia S; Meyerson H
    J Clin Pathol; 2018 Oct; 71(10):906-915. PubMed ID: 29769234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas.
    Tapia G; Lopez R; Muñoz-Mármol AM; Mate JL; Sanz C; Marginet R; Navarro JT; Ribera JM; Ariza A
    Histopathology; 2011 Oct; 59(4):672-8. PubMed ID: 22014048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma.
    Liu Y; Bian T; Zhang Y; Zheng Y; Zhang J; Zhou X; Xie J
    Diagn Pathol; 2019 Sep; 14(1):100. PubMed ID: 31484540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the gene expression of C-myc and CD38 in HL-60 cells during differentiation induced by nicotinic acid-related compounds.
    Ida C; Ogata S; Okumura K; Taguchi H
    Biosci Biotechnol Biochem; 2008 Mar; 72(3):868-71. PubMed ID: 18323656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.
    Raess PW; Moore SR; Cascio MJ; Dunlap J; Fan G; Gatter K; Olson SB; Braziel RM
    Leuk Lymphoma; 2018 Jun; 59(6):1391-1398. PubMed ID: 28868942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
    Gualco G; Weiss LM; Barber GN; Bacchi CE
    Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations: results of 298 fine needle aspirates of B-cell non-Hodgkin lymphoma.
    da Cunha Santos G; Ko HM; Geddie WR; Boerner SL; Lai SW; Have C; Kamel-Reid S; Bailey D
    Cancer Cytopathol; 2010 Oct; 118(5):250-8. PubMed ID: 20862704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner.
    Boström H; Leuchowius KJ; Hallböök H; Nordgren A; Thörn I; Thorselius M; Rosenquist R; Söderberg O; Sundström C
    Eur J Haematol; 2008 Sep; 81(3):218-25. PubMed ID: 18510704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
    Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
    J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.
    Menter T; Medani H; Ahmad R; Flora R; Trivedi P; Reid A; Naresh KN
    Br J Haematol; 2017 Nov; 179(4):681-684. PubMed ID: 27447126
    [No Abstract]   [Full Text] [Related]  

  • 20. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
    Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
    Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.